EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitScoping ReviewOpen Access · CC BY 4.0

Factors influencing FDA drug approval decisions beyond clinical trial evidence: a scoping review

Robin Forrest iD, Martin Lodge iD, Ameet Sarpatwari iD, Huseyin Naci iD

Health Affairs Scholar · 03.08.2026 · 4 (8)

DOI: 10.1093/haschl/qxag201 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Health Affairs Scholar, online erschienen am 04.08.2026. Verfasst von Robin Forrest und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy, The London School of Economics, London WC2A 2AE, United Kingdom. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Food and Drug Administration's (FDA) approval decisions are expected to rest primarily on clinical evidence, yet concerns persist about whether political pressure, commercial interests, or institutional dynamics also influence the approval process.

Methods

We conducted a scoping review of empirical studies published between 1990 and 2025 evaluating factors other than clinical evidence in FDA drug approval decisions, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework.

Results

Fifteen studies examined 5 categories of factors: firm-level attributes, FDA organizational structures, procedural factors, regulatory reforms, and external pressures including media attention and political salience. Most studies (10/15) evaluated these factors using speed of FDA drug approval as a primary outcome, rather than the decision to approve or reject, or a measure of decision quality. Findings were mixed, with the most consistent evidence for close agreement between advisory committee recommendations and approval decisions, identified across independent research teams. More limited evidence also suggested external stakeholder pressure may affect review times.

Conclusion

A paucity of empirical evidence likely points to the inherent difficulty of demonstrating influence on agency decision-making. More research is needed to evaluate the potential influence of factors beyond clinical evidence on approval decisions, and the extent to which these decisions ultimately benefit patients.

Schlagwörter

Stichwörter der Autor:innen

FDAUS Food and Drug Administrationdrug approval processpharmaceutical policyregulationregulatory agencies

Autor:innen und Institutionen

  • Department of Health Policy, The London School of Economics, London WC2A 2AE, United Kingdom.
  • Department of Government and Centre for Analysis of Risk and Regulation, The London School of Economics, London WC2A 2AE, United Kingdom.
  • Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, United States.

ORCID-Profile: Robin Forrest, Martin Lodge, Ameet Sarpatwari, Huseyin Naci

Zitieren

APA

Forrest, R., Lodge, M., Sarpatwari, A., & Naci, H. (2026). Factors influencing FDA drug approval decisions beyond clinical trial evidence: a scoping review. Health Affairs Scholar, 4(8). https://doi.org/10.1093/haschl/qxag201

Vancouver

Forrest R, Lodge M, Sarpatwari A, Naci H. Factors influencing FDA drug approval decisions beyond clinical trial evidence: a scoping review. Health Affairs Scholar. 2026;4(8). doi:10.1093/haschl/qxag201

BibTeX
@article{Forrest2026,
  author = {Forrest, Robin and Lodge, Martin and Sarpatwari, Ameet and Naci, Huseyin},
  title = {Factors influencing FDA drug approval decisions beyond clinical trial evidence: a scoping review},
  journal = {Health Affairs Scholar},
  year = {2026},
  volume = {4},
  number = {8},
  doi = {10.1093/haschl/qxag201}
}
Kostenlos starten →